Gemfibrozil, stretching arms beyond lipid lowering

References

• Hodges, R.M. Gemfibrozil—A new lipid lowering agent. Proc.Royal Soc.Med. 1976, 69 Suppl 2, 1–2.
   Google Scholar
• Betteridge, D.J., Higgins, M.J., Galton, D.J. Properties of sterol biosynthesis in human leukocytes, effects of gemfibrozil. Proc. Royal Soc. Med.1976, 69 Suppl 2, 104–106.
   Google Scholar
• Auwerx, J. Regulation of gene expression by fatty acids and fibric acid derivatives, an integrative role for peroxisome proliferator activated receptors. The Belgian Endocrine Society Lecture 1992. Hormone Res. 1992, 38(5–6), 269–277.
   Google Scholar
• Xu, H.E., Lambert, M.H., Montana, V.G., et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. NAS USA . 2001, 98(24), 13919–13924.
   Google Scholar
• Hostetler, H.A., Petrescu, A.D., Kier, A.B., Schroeder, F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands. J Biol Chem. 2005, 280(19), 18667–18682.
   Google Scholar
• Pawar, A., Jump, D.B. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes. J. Biol. Chem . 2003, 278(38), 35931–35939.
   Google Scholar
• Gottlicher, M., Demoz, A., Svensson, D., Tollet, P., Berge, R.K., Gustafsson, J.A. Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem. Pharmacol. 1993, 46(12), 2177–2184.
   Google Scholar
• Scatena, R., Bottoni, P., Martorana, G.E., et al. Mitochondria, ciglitazone and liver, a neglected interaction in biochemical pharmacology. Eur. J. Pharmacol . 2007, 567(1–2), 50–58.
   Google Scholar
• Zoete, V., Grosdidier, A., Michielin, O. Peroxisome proliferator-activated receptor structures, ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta. 2007, 1771(8), 915–925.
   Google Scholar
• Nash, D.T. Hyperlipoproteinemia, atherosclerosis and gemfibrozil. Angiology. 1982, 33(9), 594–602.
   Google Scholar
• DeSalcedo, I., Gorringe, A.L., Silva, J.L., Santos, J.A. Gemfibrozil in a group of diabetics. Proc.Royal Soc.Med. 1976, 69 Suppl 2, 64–70.
   Google Scholar
• Miller-Blair, D., White, R., Greenspan, A. Acute gout involving the acromioclavicular joint following treatment with gemfibrozil. J. Rheum. 1992, 19(1), 166–168.
   Google Scholar
• Dellavalle, R.P., Nicholas, M.K., Schilling, L.M. Melanoma chemoprevention, a role for statins or fibrates? Am. J. Therapeutics . 2003, 10(3), 203–210.
   Google Scholar
• Dasgupta, S., Roy, A., Jana, M., Hartley, D.M., Pahan, K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Molec. Pharmacol. 2007, 72(4), 934–946.
   Google Scholar
• Strauss, J.F., Liu, P., Christenson, L.K., Watari, H. Sterols and intracellular vesicular trafficking, lessons from the study of NPC1. Steroids. 2002, 67(12), 947–951.
   Google Scholar
• Ioannou, Y. Multidrug permeases and subcellular cholesterol transport. Nature Rev. Molec. Cell Biol. 2001, 2(9), 657–668.
   Google Scholar
• Schmitz, G., Grandl, M. Lipid homeostasis in macrophages — Iimplications for atherosclerosis. Rev Physiol Biochem. Pharmacol. 2008, 160, 93–125.
   Google Scholar
• Chinetti-Gbaguidi, G., Rigamonti, E., Helin, L., et al. Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 2005, 46(12), 2717–2725.
   Google Scholar
• Rigamonti, E., Chinetti-Gbaguidi, G., Staels, B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterio., Thromb. Vasc. Biol. 2008, 28(6), 1050–1059.
   Google Scholar
• Hossain, M.A., Tsujita, M., Gonzalez, F.J., Yokoyama, S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 2008, 51(3), 258–266.
   Google Scholar
• Oram, J.F., Lawn, R.M. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 2001, 42(8), 1173–1179.
   Google Scholar
• Venkateswaran, A., Laffitte, B.A., Joseph, S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. NAS USA 2000, 97(22), 12097–12102.
   Google Scholar
• Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., Beylot, M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes. 2002, 51(12), 3486–3491.
   Google Scholar
• van Meer, G. Caveolin, cholesterol, and lipid droplets? J. Cell Biol. 2001, 152(5), F29–34.
   Google Scholar
• Lee, O., Chang, C.C., Lee, W., Chang, T.Y. Immunodeple tion experiments suggest that acyl-coenzyme A, cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J. Lipid Res. 1998, 39(8), 1722–1727.
   Google Scholar
• Chinetti, G., Lestavel, S., Fruchart, JC., Clavey, V., Staels, B. Peroxisome proliferator–activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res. 2003, 92(2), 212–217.
   Google Scholar
• Mandel, H., Getsis, M., Rosenblat, M., Berant, M., Aviram, M. Reduced cellular cholesterol content in peroxisome-deficient fibroblasts is associated with impaired uptake of the patient’s low density lipoprotein and with reduced cholesterol synthesis. J. Lipid Res. 1995, 36(6), 1385–1391.
   Google Scholar
• Hashimoto, F., Hamada, S., Hayashi, H. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. Biol. Pharmaceut. Bull. 1997, 20(4), 315–321.
   Google Scholar
• Aoyama, T., Peters, J.M., Iritani, N., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998, 273(2), 5678–5684.
   Google Scholar
• Jones, D.P. Intracellular catalase function, analysis of the catalatic activity by product formation in isolated liver cells. Arch. Biochem. Biophys. 1982, 214(2), 806–814.
   Google Scholar
• Brady, P.S., Ramsay, R.R., Brady, L.J. Regulation of the long-chain carnitine acyltransferases. FASEB J. 1993, 7(11), 1039–1044.
   Google Scholar
• Kamijo, K., Taketani, S., Yokota, S., Osumi, T., Hashimoto, T. The 70-kDa peroxisomal membrane protein is a member of the Mdr (P-glycoprotein)-related ATP-binding protein superfamily. J. Biol. Chem. 1990, 265(8), 4534–4540.
   Google Scholar
• Latruffe, N., Cherkaoui Malki, M., Nicolas-Frances, V., Clemencet, M.C., Jannin, B., Berlot, J.P. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Biochem. Pharmacol. 2000, 60(8), 1027–1032.
   PubMedGoogle Scholar
• Burns, K.A., Vanden Heuvel, J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta . 2007, 1771(8), 952–960.
   Google Scholar
• Jin, F.Y., Kamanna, V.S., Chuang, M.Y., Morgan, K., Kashyap, M.L. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler., Thromb., Vasc. Biol. 1996, 16(8), 1052–1062.
   Google Scholar
• Saku, K., Gartside, P.S., Hynd, B.A., Kashyap, M.L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin. Invest. 1985, 75(5), 1702–1712.
   Google Scholar
• Xiao, J., Zhang, F., Wiltshire, S., et al. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. Atherosclerosis. 2008, 199(2), 333–339.
   Google Scholar
• Robins, S.J., Collins, D., Wittes, J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events, VA-HIT, a randomized controlled trial. JAMA. 2001, 285(12), 1585–1591.
   Google Scholar
• Frick, M.H., Elo, O., Haapa, K., et al. Helsinki Heart Study, primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med.1987, 317(20), 1237–1245.
   PubMed Web of Science ®Google Scholar
• Pahan, K., Jana, M., Liu, X., Taylor, BS., Wood, C., Fischer, S.M. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J. Biol. Chem. 2002, 277(48), 45984–45991.
   Google Scholar
• Xu, J., Racke, M.K., Drew, P.D. Peroxisome proliferator- activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS, relevance to multiple sclerosis. J. Neurochem. 2007, 103(5), 1801–1810.
   Google Scholar
• Xu, J., Chavis, J.A., Racke, M.K., Drew, P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 2006, 176(12), 95–105.
   Google Scholar
• Jana, M., Jana, A., Liu, X., Ghosh, S., Pahan, K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J. Immunol. 2007, 179(6), 4142–4152.
   Google Scholar
• Yang, Y., Gocke, AR., Lovett-Racke, A., Drew, PD., Racke, M.K. PPAR Alpha regulation of the immune response and autoimmune encephalomyelitis. PPAR Res. 2008, 2008,546753.
   Google Scholar
• Drew, P.D., Xu, J., Storer, P.D., Chavis, J.A., Racke, M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders. Neurochem. Int. 2006, 49(2), 183–189
   Google Scholar
• Bloomfield Rubins, H., Davenport, J., Babikian, V., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001, 103(23), 2828–2833.
   Google Scholar
• Cunard, R. The potential use of PPARalpha agonists as immunosuppressive agents. Curr. Opin. Investigat. Drugs. 2005, 6(5), 467–472.
   Google Scholar
• Calkin, A.C., Cooper, M.E., Jandeleit-Dahm, K.A., Allen, T.J. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 2006, 49(4), 766–774.
   Google Scholar
• Watkins, B.A., Dorn, H.H., Kelly, W.B., et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science. 1990, 249(4968), 549–553.
   Google Scholar
• Pencalet, P., Serguera, C., Corti, O., Privat, A., Mallet, J., Gimenez, y Ribotta M. Integration of genetically modified adult astrocytes into the lesioned rat spinal cord. J. Neurosci. Res. 2006, 83(1), 61–67.
   Google Scholar
• Roy, A., Fung, Y.K., Liu, X., Pahan, K. Up-regulation of microglial CD11b expression by nitric oxide. J. Biol. Chem. 2006, 281(21), 14971–14980.
   Google Scholar
• Brahmachari, S., Fung, Y.K., Pahan, K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J. Neurosci2006, 26(18), 4930–4939.
   Google Scholar
• Pahan, K., Sheikh, F.G., Liu, X., Hilger, S., McKinney, M., Petro, T.M. Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J. Biol. Chem. 2001, 276(11), 7899–7905.
   Google Scholar
• Jackson, T.C., Mi, Z., Bastacky, S.I., McHale, T., Melhem, M.F., Sonalker, P.A., Tofovic, S.P., Jackson, E.K. PPAR alpha agonists improve renal preservation in kidneys subjected to chronic in vitro perfusion: interaction with mannitol. Transplant Intern. 2007, 20(3), 277–90.
   Google Scholar
• Okamoto, H., Kamatani, N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63(8), 1002–1003.
   Google Scholar
• Deans, K.A., Sattar, N. “Anti-inflammatory” drugs and their effects on type 2 diabetes. Diabetes Technol. Therapeut. 2006, 8(1), 18–27.
   Google Scholar
• Neve, B.P., Fruchart, J.C., Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol. 2000, 60(8), 1245–1250.
   Google Scholar
• Dasgupta, S., Zhou, Y., Jana, M., Banik, N.L., Pahan, K. Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J. Immunol. 2003, 170(7), 3874–82.
   Google Scholar
• Racke, M., Gocke, A., Muir, M., Diab, A., Drew, P., Lovett-Racke, A. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutrition. 2006, 136, 700–703.
   PubMedGoogle Scholar
• Dasgupta, S., Jana, M., Liu, X., Pahan, K. Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells. Implications for multiple sclerosis. J. Biol. Chem. 2002, 277(42), 39327–39333
   Google Scholar
• Roy, A., Liu, X., Pahan, K. Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 [corrected]integrin. J. Biol. Chem. 2007, 282(44), 32222–32232.
   Google Scholar
• Heyworth, P.G., Bohl, B.P., Bokoch, G.M., Curnutte, J.T. Rac translocates independently of the neutrophil NADPH oxidase components p47phox and p67phox. Evidence for its interaction with flavocytochrome b558. J. Biol. Chem. 1994, 269(49), 30749–30752.
   Google Scholar
• Kleinberg, M.E., Malech, H.L., Mital, D.A., Leto, T.L. p21rac does not participate in the early interaction between p47-phox and cytochrome b558 that leads to phagocyte NADPH oxidase activation in vitro. Biochemistry. 1994, 33(9), 2490–2495.
   Google Scholar
• Kervinen, H., Huittinen, T., Vaarala, O., et al. Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk. Atherosclerosis. 2003, 169(2), 339–344.
   Google Scholar
• Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998, 138(2), 271–280.
   Google Scholar
• Balogh, Z., Seres, I., Harangi, M., Kovacs, P., Kakuk, G., Paragh, G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 2001, 27(5), 604–610.
   Google Scholar
• Mowri, H.O., Frei, B., Keaney, J.F. Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radical Biol. Med. 2000, 29(9), 814–824.
   Google Scholar
• Wolff, S.P., Jiang, Z.Y., Hunt, J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad. Biol. Med. 1991, 10(5), 339–352.
   Google Scholar
• Requena, J.R., Fu, M.X., Ahmed, M.U., et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem. J. 1997, 322 ( Pt 1), 317–325.
   Google Scholar
• Hunter, M.I., Nlemadim, B.C., Davidson, D.L. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem. Res.1985, 10(12), 1645–1652.
   Google Scholar
• Toshniwal, P.K., Zarling, E.J. Evidence for increased lipid peroxidation in multiple sclerosis. Neurochem. Res. 1992, 17(5), 205–207.
   Google Scholar
• Yoshida, H., Ishikawa, T., Ayaori, M., et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein, a randomized, double-blind, placebo-controlled study. Atherosclerosis. 1998, 139(1), 179–187.
   Google Scholar
• Gouedard, C., Koum-Besson, N., Barouki, R., Morel, Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molec. Pharmacol. 2003, 63(4), 945–956.
   Google Scholar
• Marx, N., Sukhova, G.K., Collins, T., Libby, P., Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999, 99(24), 3125–3131.
   Google Scholar
• Marchesi, S., Lupattelli, G., Lombardini, R., et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J. Clin. Pharmacy Therapeut. 2003, 28(5), 419–424.
   Google Scholar
• Pasceri, V., Cheng, J.S., Willerson, J.T., Yeh, E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti- atherosclerosis drugs. Circulation. 2001, 103(21), 2531–2534.
   Google Scholar
• Han, S.H., Quon, M.J., Koh, K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension. 2005, 46(5), 1086–1092.
   Google Scholar
• Pahan, K. Lipid-lowering drugs. Cellular Molec. Life Sci. 2006, 63, 1165–1178.
   PubMed Web of Science ®Google Scholar
• Ye, H.J., Zhao, S.P. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. Med. Hypotheses. 2006, 66(3), 495–500.
   Google Scholar
• Ryoo, S.W., Kim, D.U., Won, M., et al. Native LDL induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. Cardiovasc Res. 2004, 62(1), 185–193.
   Google Scholar
• Ryoo, S., Won, M., Kim, D.U., et al. PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem. Biophys. Res. Communs. 2004, 318(2), 329–334.
   Google Scholar
• Sumanasekera, W.K., Tien, E.S., Davis, J.W., Turpey, R., Perdew, G.H., Vanden Heuvel, JP. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator- activated receptor-alpha (PPARalpha) and PPARbeta activity. Biochemistry. 2003, 42(36), 10726–10735.
   Google Scholar
• Hossain, M.A, Tsujita, M., Gonzalez, F.J., Yokoyama, S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J. Cardiovasc. Pharmacol. 2008, 51(3):258–66.
   Google Scholar
• Tordjman, K., Bernal-Mizrachi, C., Zemany, L., et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 2001, 107(8)(7), 1025–1034.
   Google Scholar
• Oshio, H., Abe, T., Onogawa, T et al. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines. J. Gastroenterol. 2008, 43, 538–549.
   Google Scholar
• Mohan, W.S., Chen, Z.Q., Zhang, X., et al. Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter, role of gemfibrozil. J. Lipid Res. 1998, 39(2), 255–267.
   Google Scholar
• Maher, J.M., Cheng, X., Slitt, A.L., Dieter, M.Z., Klaassen, C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Disposition. 2005, 33(7), 956–62
   Google Scholar
• Shek, A., Ferrill, M.J. Statin-fibrate combination therapy. Ann. Pharmacother. 2001, 35(7-8), 908–917.
   Google Scholar
• Broeders, N., Knoop, C., Antoine, M., Tielemans, C., Abramowicz, D. Fibrate-induced increase in blood urea and creatinine, is gemfibrozil the only innocuous agent? Nephrol. Dialysis Transplantation 2000, 15(12), 1993–1999.
   Google Scholar
• Dube, M., Fenton, M. Lipid abnormalities. Clin. Infect. Dis. 2003, 36(Suppl 2), S79–83.
   Google Scholar
• Knauf, H., Kolle, E.U., Mutschler, E. Gemfibrozil absorption and elimination in kidney and liver disease. Klinische Wochenschrift. 1990, 68(13), 692–698.
   Google Scholar
• Saadi, H.F., Kurlander, D.J., Erkins, J.M., Hoogwerf, B.J. Severe hypertriglyceridemia and acute pancreatitis during pregnancy, treatment with gemfibrozil. Endocr. Pract. 1999, 5(1), 33–36.
   Google Scholar
• Freeman, S.R., Drake, A.L., Heilig, L.F., et al. Statins, fibrates, and melanoma risk, a systematic review and meta-analysis. J. NCI. 2006, 98(21), 1538–1546.
   Google Scholar
• Leiss, O., von Bergmann, K., Gnasso, A., Augustin, J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism. 1985, 34(1), 74–82.
   Google Scholar
• Reddy, J.K., Mannaerts, G.P. Peroxisomal lipid metabolism. Ann. Rev. Nutrition. 1994, 14, 343–370.
   PubMed Web of Science ®Google Scholar
• Braun, L., Mile, V., Schaff, Z., et al. Induction and peroxisomal appearance of gulonolactone oxidase upon clofibrate treatment in mouse liver. FEBS Lett. 1999, 458(3), 359–362.
   Google Scholar
• Gonzalez, F.J., Peters, J.M., Cattley, R.C. Mechanism of action of the nongenotoxic peroxisome proliferators, role of the peroxisome proliferator-activator receptor alpha. J. NCI. 1998, 90(22), 1702–1709.
   PubMedGoogle Scholar
• Asif, A.R., Armstrong, V.W., Voland, A., Wieland, E., Oellerich, M., Shipkova, M. Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie. 2007, 89(3), 393–402.
   Google Scholar
• Thomas, B.F., Burgess, J.P., Coleman, D.P., Scheffler, N.M., Jeffcoat, A.R., Dix, K.J. Isolation and identification of novel metabolites of gemfibrozil in rat urine. Drug Metab. Disposit., Biol. Fate Chems. 1999, 27(1), 147–157.
   Google Scholar